Latham & Watkins Advises Aligos Therapeutics in its Initial Public Offering

Aligos Therapeutics, Inc. has announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately $150.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. Aligos’ common stock will begin trading on the Nasdaq Global Select Market, under the ticker symbol “ALGS.” 

Latham & Watkins LLP represents Aligos Therapeutics, Inc. in the transaction with a corporate deal team led by Bay Area partner Mark Roeder, with Bay Area associates John Williams, Tess Bloom, Madelyn Tarr, and Natalie Robertson and Orange County associate Traci Biedermann. Advice was also provided on technology transactions matters by New York partner Alan Tamarelli and Bay Area partner Chris Hazuka, with Boston associate Seth Appiah-Opoku; on tax matters by Bay Area partner Kirt Switzer, with Orange County associate Janet Hsu; on benefits and compensation matters by Bay Area partner James Metz, with Bay Area associate Erik Ward; on FDA regulatory matters by Washington, D.C. partner John Manthei, with San Diego associates Amy Speros and Kiera Murphy; and on healthcare regulatory matters by Bay Area counsel Betty Pang and Heather Deixler.